Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18957404 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | November 2024 | April 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18864569 | TRIPTOLIDE LIGNOCERATE, LIPOSOME THEREOF AND PREPARATION METHOD THEREFOR | November 2024 | January 2026 | Allow | 14 | 2 | 1 | No | No |
| 18922818 | MEDICAL MATERIAL | October 2024 | July 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18908438 | ARTESUNATE POWDERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURE | October 2024 | May 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18848678 | BIOACTIVE GRANULAR HYDROGEL SCAFFOLDS AND USE THEREOF | September 2024 | April 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18825766 | LARGE-SCALE MANUFACTURING METHODS FOR AMINOGLYCOSIDES | September 2024 | September 2025 | Allow | 13 | 2 | 1 | Yes | No |
| 18833679 | ANTIBODY-BOUND LIPID NANOPARTICLE COMPRISING ANTIBODY BOUND TO MEMBRANE SCAFFOLD PROTEIN | August 2024 | July 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18762795 | MANGANESE-DOPED HOLLOW MESOPOROUS SILICA NANOPARTICLES LOADED WITH CURCUMIN | July 2024 | November 2024 | Allow | 5 | 1 | 0 | No | No |
| 18761863 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | July 2024 | October 2024 | Allow | 3 | 1 | 1 | Yes | No |
| 18761882 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | July 2024 | November 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18676591 | Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin | May 2024 | April 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18651154 | METHODS FOR DECREASING INJURIES ASSOCIATED WITH INTRAOPERATIVE HYPOTENSION | April 2024 | November 2025 | Allow | 18 | 2 | 0 | Yes | Yes |
| 18636721 | Atomic Scale Topical Composition with Enhanced Interstitial Cellular Uptake for Increased Moisturizing, Fluidity, Antioxidant and Radiation Protection, Antimicrobial Cleansing and Therapeutics for Optimal Dermal Integrity and Homeostasis. | April 2024 | November 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18613609 | Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan | March 2024 | November 2025 | Abandon | 20 | 4 | 0 | Yes | No |
| 18607029 | CANCER THERAPY COMPOSITIONS AND USES THEREOF | March 2024 | August 2025 | Allow | 17 | 3 | 1 | No | No |
| 18583453 | GREEN SYNTHESIS OF SILVER NANOPARTICLES ENCAPSULATED IN A NANOSTRUCTURED LIPID CARRIER | February 2024 | September 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18443850 | ARTESUNATE POWDERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURE | February 2024 | September 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18436704 | COMPOSITION CONTAINING ANTITUMOR DRUG, AND PREPARATION METHOD THEREOF AND USE THEREOF | February 2024 | April 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18432899 | BLOCK COPOLYMERS AND USES THEREOF | February 2024 | May 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18544197 | COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE | December 2023 | April 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18503327 | LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES | November 2023 | October 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18289200 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | November 2023 | October 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18377679 | PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND WITH DOUBLE CORESHELL STRUCTURE AND METHOD FOR MANUFACTURING THE SAME | October 2023 | January 2026 | Abandon | 27 | 1 | 0 | No | No |
| 18375788 | NANO-PARTICLES THAT CONTAIN SYNTHETIC VARIANTS OF GM3 GANGLIOSIDE AS ADJUVANTS IN VACCINES | October 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18458767 | LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES | August 2023 | January 2026 | Abandon | 29 | 2 | 1 | No | No |
| 18456371 | Synthetic Nanostructures Including Nucleic Acids and/or Other Entities | August 2023 | August 2025 | Abandon | 24 | 5 | 0 | No | No |
| 18547664 | BISPECIFIC NANOPARTICLE SYSTEMS FOR TARGETING CANCER CELLS | August 2023 | January 2026 | Allow | 29 | 1 | 1 | Yes | No |
| 18235980 | HYBRID BIOLOGICAL MEMBRANES, METHODS OF MAKING AND USES THEREOF | August 2023 | October 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18232877 | Atomic Scale Topical Composition with Enhanced Interstitial Cellular Uptake for Increased Moisturizing, Fluidity, Antioxidant and Radiation Protection, Antimicrobial Cleansing and Therapeutics for Optimal Dermal Integrity and Homeostasis | August 2023 | December 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18365187 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | August 2023 | November 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18363531 | BHB LIPOSOMES AND PREPARATION METHODS THEREOF | August 2023 | March 2026 | Allow | 32 | 1 | 1 | Yes | No |
| 18263649 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | July 2023 | February 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18225749 | PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA | July 2023 | March 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18225585 | Methods of Treating Inflammatory Disorders and Global Inflammation with Compositions Comprising Phospholipid Nanoparticle Encapsulations of Anti-Inflammatory Nutraceuticals | July 2023 | November 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18222839 | AMINO ALCOHOL IONIZABLE LIPIDS | July 2023 | March 2026 | Abandon | 32 | 0 | 1 | No | No |
| 18221262 | NONCOMPETITIVE RECEPTOR-TARGETED VACCINE DELIVERY TO PLASMACYTOID DENDRITIC CELLS | July 2023 | November 2025 | Allow | 28 | 1 | 0 | No | No |
| 18343349 | Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune Responses | June 2023 | March 2025 | Abandon | 21 | 3 | 0 | Yes | No |
| 18259346 | REDUCED GRAPHENE OXIDE (rGO) BASED DRUG CARRIER SYSTEMS | June 2023 | November 2025 | Allow | 29 | 1 | 0 | No | No |
| 18214021 | Method of Synthesis of a Nanocomposite including Silymarin-loaded Collagen Nanoparticles | June 2023 | October 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18214060 | FREEZE-DRIED PRODUCT AND GAS-FILLED MICROVESICLES SUSPENSION | June 2023 | October 2025 | Allow | 28 | 2 | 0 | No | No |
| 18338485 | METHODS OF MAKING LIPID NANOPARTICLES | June 2023 | February 2025 | Allow | 20 | 2 | 0 | No | No |
| 18329969 | Semisolid Oral Dispersions Comprising Active Agents | June 2023 | July 2025 | Allow | 25 | 2 | 0 | No | No |
| 18038978 | COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING LIPID NANOPARTICLES | May 2023 | January 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18038979 | LIPID NANOPARTICLES COMPRISING MANNOSE OR USES THEREOF | May 2023 | February 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18196235 | LIPID NANOPARTICLES | May 2023 | January 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18297255 | COMPOUNDS AND COMPOSITIONS FOR DRUG DELIVERY | April 2023 | February 2025 | Abandon | 22 | 4 | 1 | Yes | No |
| 18193689 | METHOD FOR FORMING A NANOMEDICINAL COMPOSITION | March 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18193692 | METHOD FOR TREATING BLASTOCYSTIS INFECTION | March 2023 | August 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18191517 | Structure-Function Relationships in the Development of Immunotherapeutic Agents | March 2023 | June 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18190219 | DELIVERY SYSTEM FOR USE IN MEDICINE | March 2023 | August 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18120298 | NANOFORMULATION OF SPRIOOXINDOLE AND METHODS FOR TREATING HEPATOCELLULAR CARCINOMA | March 2023 | November 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18181163 | LIPOSOMAL COMPOSITION FOR USE IN A METHOD OF TREATING PARKINSON'S DISEASE | March 2023 | January 2026 | Allow | 35 | 2 | 0 | No | No |
| 18114434 | PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA | February 2023 | December 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18021613 | AMPHIPHILIC MATERIAL AND APPLICATION THEREOF IN PREPARATION FOR LIPOSOME | February 2023 | March 2024 | Allow | 13 | 2 | 0 | No | No |
| 18107353 | SUSTAINED RELEASE PARTICLE FORMULATIONS | February 2023 | June 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 18104620 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | February 2023 | October 2025 | Abandon | 33 | 1 | 1 | No | No |
| 18100201 | Semisolid Oral Dispersions Comprising Active Agents | January 2023 | March 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18150528 | LIPID NANOPARTICLES | January 2023 | January 2026 | Allow | 36 | 1 | 1 | Yes | No |
| 18150399 | ORAL COMPOSITIONS AND THE PREPARATION METHODS THEREOF | January 2023 | January 2025 | Allow | 24 | 1 | 0 | No | No |
| 18083458 | NANOPARTICLES ENCAPSULATING SOLUBLE BIOLOGICS, THERAPEUTICS, AND IMAGING AGENTS | December 2022 | December 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17988857 | Liposomes Useful for Drug Delivery | November 2022 | February 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18054131 | LEVERAGING LIPID-PROTEIN INTERACTIONS TO ENGINEER SPATIAL ORGANIZATION IN CELL-FREE SYSTEMS | November 2022 | November 2025 | Allow | 37 | 1 | 1 | No | No |
| 17959983 | PLANT MEDIUM INCLUDING AN OXYGEN-ENABLED COMPOSITION | October 2022 | November 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17952593 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | September 2022 | January 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17941669 | COMPOSITIONS AND SYSTEMS COMPRISING TRANSFECTION-COMPETENT VESICLES FREE OF ORGANIC-SOLVENTS AND DETERGENTS AND METHODS RELATED THERETO | September 2022 | August 2023 | Allow | 11 | 2 | 1 | Yes | No |
| 17899933 | Stabilizing Camptothecin Pharmaceutical Compositions | August 2022 | October 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17886590 | COMPOSITIONS FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS AND METHODS OF MAKING SAME | August 2022 | August 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17873404 | LIPID COMPOUND AS WELL AS LIPID VECTOR, NUCLEIC ACID LIPID NANOPARTICLE COMPOSITION, AND PHARMACEUTICAL PREPARATION COMPRISING THE SAME | July 2022 | June 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17872974 | FREEZE-DRIED PRODUCT AND GAS-FILLED MICROVESICLES SUSPENSION | July 2022 | March 2023 | Allow | 8 | 1 | 0 | No | No |
| 17871768 | FUSOGENIC LIPOSOME-COATED POROUS SILICON NANOPARTICLES | July 2022 | December 2025 | Allow | 41 | 2 | 0 | No | No |
| 17813001 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | July 2022 | March 2025 | Allow | 32 | 5 | 0 | Yes | Yes |
| 17812946 | SUSTAINED DRUG DELIVERY IMPLANT | July 2022 | October 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17864524 | ANTIMICROBIAL COATING MATERIAL FOR SURFACE COATING | July 2022 | February 2026 | Allow | 43 | 2 | 1 | Yes | No |
| 17792259 | NUCLEIC ACID LOADED RED BLOOD CELL EXTRACELLULAR VESICLES | July 2022 | February 2026 | Abandon | 43 | 1 | 1 | No | No |
| 17810064 | LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES | June 2022 | May 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 17810055 | LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES | June 2022 | December 2023 | Abandon | 17 | 2 | 0 | Yes | Yes |
| 17808412 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | June 2022 | July 2024 | Allow | 25 | 1 | 0 | No | No |
| 17847808 | OXYGEN GAS SUSTAINED RELEASED NANO-EMULSION COMPOSITION AND METHOD FOR PRODUCING THE SAME | June 2022 | December 2023 | Allow | 18 | 2 | 1 | Yes | No |
| 17842876 | METAL ORGANIC FRAMEWORK/POROUS SILICATE AND/OR ALUMINOSILICATE NANOCARRIER FOR BLASTOCYSTOSIS TREATMENT | June 2022 | September 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17840700 | CAPE-LOADED TARGETED MICROVESICULAR CANCER DRUG AND METHOD FOR DEVELOPING THE SAME | June 2022 | August 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17835634 | METHOD FOR PREVENTING OR TREATING UROLOGICAL CHRONIC PELVIC PAIN SYNDROME | June 2022 | October 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17831962 | CABAZITAXEL WEAKLY- ALKALINE DERIVATIVE AND FORMULATION THEREOF | June 2022 | September 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17830615 | PROTEIN-LOADED PLGA NANOSPHERES | June 2022 | August 2024 | Allow | 27 | 5 | 0 | Yes | No |
| 17831258 | PROCESS FOR FORMULATING AN ANIONIC AGENT | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17829960 | DELIVERY OF AGENTS USING METASTABLE LIPOSOMES | June 2022 | September 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17746249 | TREATMENT OF HIP PAIN WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | May 2022 | September 2023 | Allow | 16 | 3 | 1 | Yes | No |
| 17740426 | Core Shell Silica Particles and Uses Thereof As an Anti-Bacterial Agent | May 2022 | February 2025 | Allow | 33 | 2 | 0 | No | No |
| 17775422 | CAROTENOID COMPOSITIONS AND USES THEREOF | May 2022 | October 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17727993 | METHODS OF IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTIC AGENTS | April 2022 | December 2024 | Allow | 31 | 0 | 1 | Yes | No |
| 17713679 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | April 2022 | April 2024 | Abandon | 24 | 4 | 1 | No | No |
| 17754327 | Process for preparing nanoparticles in the form of a powder comprising a bio-resorbable polyester | March 2022 | February 2024 | Allow | 22 | 4 | 0 | Yes | No |
| 17703824 | SYNTHETIC NANOSTRUCTURES INCLUDING NUCLEIC ACIDS AND/OR OTHER ENTITIES | March 2022 | January 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17761480 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING ACTIVE SUBSTANCE, POLYMER AND SURFACTANT | March 2022 | October 2025 | Allow | 43 | 1 | 1 | No | No |
| 17695999 | COMPOSITIONS FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS AND METHODS OF MAKING SAME | March 2022 | November 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17696225 | POLYMER MEDICAMENT FOR TREATING HYPERKALEMIA AND PREPARATION METHOD THEREOF | March 2022 | November 2025 | Abandon | 44 | 2 | 1 | Yes | No |
| 17684805 | TREATMENT OF HIP PAIN WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | March 2022 | September 2023 | Allow | 19 | 3 | 1 | Yes | No |
| 17589554 | ANTIFUNGAL NANOPARTICLES FOR TARGETED TREATMENT OF FUNGAL INFECTIONS | January 2022 | July 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17581482 | NANOCOMPLEXES OF POLYANION-MODIFIED PROTEINS | January 2022 | March 2025 | Abandon | 38 | 2 | 1 | No | No |
| 17579832 | ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMS | January 2022 | September 2024 | Allow | 32 | 4 | 0 | Yes | No |
| 17628559 | NANOCOMPOSITE PARTICLE AND USES THEREOF | January 2022 | October 2025 | Allow | 45 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHOMER, ISAAC.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SHOMER, ISAAC works in Art Unit 1612 and has examined 1,156 patent applications in our dataset. With an allowance rate of 61.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner SHOMER, ISAAC's allowance rate of 61.6% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SHOMER, ISAAC receive 2.50 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SHOMER, ISAAC is 31 months. This places the examiner in the 53% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +34.4% benefit to allowance rate for applications examined by SHOMER, ISAAC. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.2% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 30.2% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 64.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 64.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 72.5% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.8% of allowed cases (in the 64% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.7% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.